Zusammenfassung
Im Vergleich zu rekombinantem "Standard"-Interferon-α2b führt die Anwendung von pegyliertem Interferon-α2b zu einer signifikant erhöhten Ansprechrate in der Therapie der chronischen Hepatitis C. Häufige Nebenwirkungen der Interferontherapie sind lokale, entzündliche Hautreaktionen an der Injektionsstelle. Wir beschreiben den Fall einer 57-jährigen, an Hepatitis C erkrankten Patientin, die im Rahmen einer Therapie mit pegyliertem Interferon-α2b ein generalisiertes, makulopapulöses Arzneimittelexanthem entwickelte. In der allergologischen Testung induzierten nur pegyliertes Interferon-α2b, nicht aber herkömmliches "Standard"-Interferon-α2b eine Hautreaktion vom Spättyp.
Abstract
In comparison to recombinant "standard"-interferon-α2b, treatment with pegylated interferon-α2b significantly improves the therapeutic response of patients suffering from chronic hepatitis C. The most common side effect of interferon-α2b therapy is localized inflammatory skin lesions at sites of injection. A 57-year-old woman with hepatitis C infection developed a generalized maculopapular exanthem during the treatment with pegylated interferon-α2b. In contrast to recombinant "standard"-interferon-α2b, only pegylated interferon-α2b induced a delayed-type skin reaction during allergy testing.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Baker DE (2001) Pegylated interferons. Rev Gastroenterol Disord 1:87–99
Berger L, Descamps V, Marck Y et al. (2000) Alpha interferon-induced eczema in atopic patients infected by hepatitis C virus: 4 case reports. Ann Dermatol Venereol 27:51–55
Dereure O, Raison-Peyron N, Larrey D et al. (2002) Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol 147:1142–1146
Harris JM, Martin NE, Modi M (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539–551
Lindsay KL, Trepo C, Heintges T et al. (2001) A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. Hepatology 34:395–403
Luxon BA, Grace M, Brassard D, Bordens R (2002) Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 24:1363–1383
Manjon-Haces JA, Vazquez-Lopez F, Gomez-Diez S et al. (2001) Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus. Acta Derm Venereol 81:223
Pfeffer LM, Dinarello CA, Herberman RB et al. (1998) Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58:2489–2499
Rubinowitz AN, Naidich DP, Alinsonorin C (2003) Case report. Interferon-induced sarcoidosis. J Comput Assist Tomogr 27:279–283
Taylor C, Burns DA, Wiselka MJ (2000) Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J 76:365–367
Youngster S, Wang YS, Grace M et al. (2002) Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des 8:2139–2157
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meller, S., Erhardt, A., Auci, A. et al. Arzneimittelexanthem durch pegyliertes Interferon-α2b . Hautarzt 54, 992–993 (2003). https://doi.org/10.1007/s00105-003-0600-8
Issue Date:
DOI: https://doi.org/10.1007/s00105-003-0600-8